Our experiments revealed that GCN5L1 deleted HCC cells were more sensitive to sorafenib, while mitochondrial restricted GCN5L1 overexpression blunted sorafenib sensitivity. The gene discussed is BLOC1S1; the disease is hepatocellular carcinoma.